RXRX
Recursion Pharmaceuticals, Inc.NASDAQHealthcare$3.15+1.29%ClosedMarket Cap: $1.41B
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
1.47
P/S
18.89
EV/EBITDA
-1.33
DCF Value
$-9.79
FCF Yield
-26.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
-32.1%
Operating Margin
-869.3%
Net Margin
-864.7%
ROE
-64.0%
ROA
-43.7%
ROIC
-48.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $35.5M | 24.4% | $-108.3M | $-108.1M | $-0.21 | — |
| FY 2025 | $74.7M | -62.0% | $-648.1M | $-644.8M | $-1.44 | — |
| Q3 2025 | $5.2M | -471.8% | $-172.2M | $-162.3M | $-0.36 | — |
| Q2 2025 | $19.1M | -5.5% | $-176.2M | $-171.9M | $-0.41 | — |
| Q1 2025 | $14.7M | -48.0% | $-191.4M | $-202.5M | $-0.50 | — |
| Q4 2024 | $4.5M | -183.6% | $-183.8M | $-178.9M | $-0.53 | — |
| FY 2024 | $58.8M | 23.1% | $-479.0M | $-463.7M | $-1.69 | — |
| Q3 2024 | $26.1M | 53.7% | $-98.4M | $-95.7M | $-0.34 | — |
| Q2 2024 | $14.4M | 36.1% | $-100.5M | $-97.5M | $-0.40 | — |
| Q1 2024 | $13.5M | 17.2% | $-96.3M | $-91.4M | $-0.39 | — |
| Q4 2023 | $10.6M | 7.0% | $-98.9M | $-93.0M | $-0.40 | — |
| FY 2023 | $43.9M | 2.9% | $-350.1M | $-328.1M | $-1.58 | — |